SNYNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SNYNF
Sanofi
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 17, 2026
$39.57−1.04 (-2.56%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2025 Ended Jun 30, 2025 | Oct 27, 2025 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Oct 27, 2023 | During market hours | $11.96B | $2.01 | $2.55 |
Press releases
Announcements Sanofi filed with the SEC
Sanofi and Regeneron expand global Alliance with multiple
EX-99.1 to Form 6-K
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks
EX-99.1 to Form 6-K
1. Condensed half-year consolidated financial statements
EX-99.1 to Form 6-K
A/ Significant events of the first half of 2026
EX-99.2 to Form 6-K
Sanofi evolves its Executive Committee to support its next strategic chapter
EX-99.1 to Form 6-K
Sanofi appoints Paulo Fontoura as Global Head of R&D
EX-99.2 to Form 6-K
Sanofi launches 2026 global employee stock purchase plan
EX-99.1 to Form 6-K
Annual General Meeting of April 29, 2026
EX-99.1 to Form 6-K
2.3 billion of bond issue
EX-99.1 to Form 6-K
ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine
EX-99.1 to Form 6-K
Q1 2026: double-digit sales and business EPS growth
EX-99.1 to Form 6-K
Filing of an amendment to the French “Document d’Enregistrement Universel”
EX-99.2 to Form 6-K
Sanofi and Regeneron’s Dupixent approved in the US as the first and only
EX-99.1 to Form 6-K
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic
EX-99.3 to Form 6-K
Filing of the 2025 U.S. Form 20-F and French
EX-99.3 to Form 6-K